Table 4 Baseline characteristics of patients with an eGFR of less than 30 mL/min/1.73m2 (5-day course of remdesivir treatment)
Unmatched cohort | Propensity score-matched cohort | |||||
|---|---|---|---|---|---|---|
Remdesivir (N = 211) | Standard care (N = 206) | P value | Remdesivir (N = 50) | Standard care (N = 50) | P value | |
Age (year), median (IQR) | 76 (67–83) | 77.5 (64–85) | 0.794 | 79 (71–85.3) | 79 (64.8–85) | 0.661 |
Male, N (%) | 70 (33.2) | 91 (44.2) | 0.021 | 18 (36) | 21 (42) | 0.539 |
BMI (kg/m2), median (IQR) | 23.3 (20.6–26.6) | 22.6 (20.2–25) | 0.119 | 22.4 (19.7–26.9) | 22.5 (19.7–25.9) | 0.924 |
Underlying disease, N (%) | ||||||
Hypertension | 180 (85.3) | 150 (72.8) | 0.002 | 47 (94) | 41 (82) | 0.065 |
Diabetes mellitus | 133 (63.0) | 104 (50.5) | 0.01 | 27 (54) | 27 (54) | 0.999 |
Congestive heart disease | 18 (8.5) | 27 (13.1) | 0.132 | 6 (12) | 13 (26) | 0.074 |
Cerebrovascular accident | 38 (18.0) | 29 (14.1) | 0.274 | 8 (16) | 7 (14) | 0.779 |
Chronic liver disease | 12 (5.7) | 8 (3.9) | 0.389 | 1 (2) | 2 (4) | 0.999 |
Solid cancer | 25 (11.8) | 19 (9.2) | 0.383 | 6 (12) | 2 (4) | 0.269 |
Hematologic malignancy | 3 (1.4) | 1 (0.5) | 0.623 | 0 (0) | 0 (0) | |
ESRD (iHD or PD) | 61 (28.9) | 56 (27.2) | 0.695 | 21 (42) | 14 (28) | 0.142 |
Kidney transplantation | 8 (3.8) | 9 (4.4) | 0.766 | 0 (0) | 1 (2) | 0.999 |
Immunosuppressant use, N (%) | 12 (5.7) | 10 (4.9) | 0.704 | 1 (2) | 0 (0) | 0.999 |
Steroid use for treatmenta | 171 (81.0) | 77 (37.4) | < 0.001 | 40 (80.0) | 21 (42.0) | < 0.001 |
Charlson Comorbidity Index, score, median (IQR) | 7 (5–8) | 7 (5–8) | 0.499 | 7 (5–9) | 7 (6–8) | 0.473 |
Baseline severity | ||||||
NEWS-2 score at admission, median (IQR) | 5 (2–8) | 2 (1–7) | < 0.001 | 4 (1.8–7) | 4 (1–8.3) | 0.895 |
Disease severity scores, median (IQR) | 3 (2–3) | 2 (1–3) | < 0.001 | 3 (2–4) | 2.5 (1–3.3) | 0.338 |
Pneumonia, N (%) | 172/207 (83.1) | 169/204 (82.8) | 0.947 | 41 (82) | 35 (70) | 0.160 |
Oxygen requirement, N (%) | 127 (60.2) | 71 (34.5) | < 0.001 | 30 (60) | 25 (50) | 0.315 |
No oxygen requirement | 84 (39.8) | 135 (65.5) | < 0.001 | 20 (40) | 25 (50) | 0.294 |
Nasal cannula | 102 (48.3) | 46 (22.3) | 21 (42) | 14 (28) | ||
Facial mask | 11 (5.2) | 10 (4.9) | 5 (10) | 4 (8) | ||
High flow nasal cannula | 8 (3.8) | 11 (5.3) | 1 (2) | 5 (10) | ||
Invasive ventilation | 6 (2.8) | 4 (1.9) | 3 (6) | 2 (4) | ||
ECMO | 0 (0) | 0 (0) | 0 (0) | 0 (0) | ||
Initial laboratory result, median (IQR) | ||||||
Creatinine (mg/dL) | 3.2 (2.4–6) | 3.1 (2.4–6.8) | 0.864 | 3 (2.8–7.3) | 3 (2–7.3) | 0.532 |
AST (IU/L) | 35 (23.3–53.8) | 26 (18–41.5) | < 0.001 | 32 (21.8–47.3) | 27.5 (18–41.8) | 0.187 |
ALT (IU/L) | 18 (13–28) | 16 (11–24) | 0.039 | 16 (11.8–25.3) | 16 (12–23.3) | 0.733 |
eGFR (mL/min/1.73m2) | 18 (8–24) | 18 (7–24) | 0.436 | 16.5 (7.8–22) | 18.5 (7–24.3) | 0.392 |